These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 32729817

  • 1. Serum Klotho is correlated to cardiovascular complications of chronic kidney disease in children.
    Okarska-Napierała M, Skrzypczyk P, Pietrzak R, Stelmaszczyk-Emmel A, Górska E, Werner B, Pańczyk-Tomaszewska M.
    Clin Nephrol; 2020 Oct; 94(4):163-172. PubMed ID: 32729817
    [Abstract] [Full Text] [Related]

  • 2. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R, Tan SJ, Hawley CM, Johnson DW, Stanton T, Lee K, Mudge DW, Campbell S, Elder GJ, Toussaint ND, Isbel NM.
    BMC Nephrol; 2017 Sep 04; 18(1):281. PubMed ID: 28870151
    [Abstract] [Full Text] [Related]

  • 3. Fibroblast growth factor 23 is associated with left ventricular hypertrophy, not with uremic vasculopathy in peritoneal dialysis patients.
    Sarmento-Dias M, Santos-Araújo C, Poínhos R, Oliveira B, Silva IS, Silva LS, Sousa MJ, Correia F, Pestana M.
    Clin Nephrol; 2016 Mar 04; 85(3):135-41. PubMed ID: 26833300
    [Abstract] [Full Text] [Related]

  • 4. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y, Olauson H, Vavilis G, Hammar U, Herthelius M, Axelsson J, Bárány P.
    Pediatr Nephrol; 2018 Jan 04; 33(1):147-157. PubMed ID: 28795324
    [Abstract] [Full Text] [Related]

  • 5. [Mineral metabolism in patients on chronic peritoneal dialysis].
    Ceballos O ML, Rojo L A, Azócar P M, Ibacache M MJ, Delucchi B A, Quiroz Z L, Irarrázabal M C, Delgado B I, Ugarte P F, Cano Sch F.
    Rev Chil Pediatr; 2014 Feb 04; 85(1):31-9. PubMed ID: 25079181
    [Abstract] [Full Text] [Related]

  • 6. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
    Kim HJ, Kang E, Oh YK, Kim YH, Han SH, Yoo TH, Chae DW, Lee J, Ahn C, Oh KH.
    BMC Nephrol; 2018 Mar 05; 19(1):51. PubMed ID: 29506503
    [Abstract] [Full Text] [Related]

  • 7. Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1-3.
    Pluta A, Stróżecki P, Krintus M, Odrowąż-Sypniewska G, Manitius J.
    Ren Fail; 2015 Aug 05; 37(7):1105-10. PubMed ID: 26156686
    [Abstract] [Full Text] [Related]

  • 8. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.
    Seifert ME, de las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.
    Am J Nephrol; 2014 Aug 05; 39(5):392-9. PubMed ID: 24818573
    [Abstract] [Full Text] [Related]

  • 9. The Association between Nitric Oxide Pathway, Blood Pressure Abnormalities, and Cardiovascular Risk Profile in Pediatric Chronic Kidney Disease.
    Hsu CN, Lu PC, Lo MH, Lin IC, Tain YL.
    Int J Mol Sci; 2019 Oct 24; 20(21):. PubMed ID: 31653115
    [Abstract] [Full Text] [Related]

  • 10. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.
    Sinha MD, Turner C, Booth CJ, Waller S, Rasmussen P, Goldsmith DJ, Simpson JM.
    Pediatr Nephrol; 2015 Oct 24; 30(10):1843-52. PubMed ID: 25975437
    [Abstract] [Full Text] [Related]

  • 11. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY, Milovanov YS, Kudryavtseva DV, Markina MM, Milovanova SY, Kozlovskaya LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA.
    Ter Arkh; 2015 Oct 24; 87(6):10-16. PubMed ID: 26281189
    [Abstract] [Full Text] [Related]

  • 12. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.
    Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N.
    PLoS One; 2016 Oct 24; 11(7):e0156860. PubMed ID: 27400031
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular alterations do exist in children with stage-2 chronic kidney disease.
    Taşdemir M, Eroğlu AG, Canpolat N, Konukoğlu D, Ağbaş A, Sevim MD, Çalışkan S, Sever L.
    Clin Exp Nephrol; 2016 Dec 24; 20(6):926-933. PubMed ID: 26822545
    [Abstract] [Full Text] [Related]

  • 14. Isolated nocturnal and isolated daytime hypertension associate with altered cardiovascular morphology and function in children with chronic kidney disease: findings from the Cardiovascular Comorbidity in Children with Chronic Kidney Disease study.
    Düzova A, Karabay Bayazit A, Canpolat N, Niemirska A, Kaplan Bulut I, Azukaitis K, Karagoz T, Oguz B, Erdem S, Anarat A, Ranchin B, Shroff R, Djukic M, Harambat J, Yilmaz A, Yildiz N, Ozcakar B, Büscher A, Lugani F, Wygoda S, Tschumi S, Zaloszyc A, Jankauskiene A, Laube G, Galiano M, Kirchner M, Querfeld U, Melk A, Schaefer F, Wühl E, 4C Study Consortium.
    J Hypertens; 2019 Nov 24; 37(11):2247-2255. PubMed ID: 31205198
    [Abstract] [Full Text] [Related]

  • 15. Soluble Klotho levels in diabetic nephropathy: relationship with arterial stiffness.
    Inci A, Sari F, Olmaz R, Coban M, Dolu S, Sarikaya M, Ellidag HY.
    Eur Rev Med Pharmacol Sci; 2016 Jul 24; 20(15):3230-7. PubMed ID: 27466997
    [Abstract] [Full Text] [Related]

  • 16. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].
    Gan L, Zhou Q.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep 28; 42(9):1058-1065. PubMed ID: 28989152
    [Abstract] [Full Text] [Related]

  • 17. FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.
    Desbiens LC, Sidibé A, Ung RV, Fortier C, Munger M, Wang YP, Bisson SK, Marquis K, Agharazii M, Mac-Way F.
    Osteoporos Int; 2018 Oct 28; 29(10):2345-2353. PubMed ID: 29959497
    [Abstract] [Full Text] [Related]

  • 18. The Association of Fibroblast Growth Factor 23 with Arterial Stiffness and Atherosclerosis in Patients with Autosomal Dominant Polycystic Kidney Disease.
    Coban M, Inci A, Yılmaz U, Asilturk E.
    Kidney Blood Press Res; 2018 Oct 28; 43(4):1160-1173. PubMed ID: 30064143
    [Abstract] [Full Text] [Related]

  • 19. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
    Han X, Cai C, Xiao Z, Quarles LD.
    J Mol Cell Cardiol; 2020 Jan 28; 138():66-74. PubMed ID: 31758962
    [Abstract] [Full Text] [Related]

  • 20. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M, Große Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, Klintschar M, Becker JU, Erbersdobler A, Aufricht C, Seeman T, Fischer DC, Faul C, Haffner D.
    Nephrol Dial Transplant; 2016 Jul 28; 31(7):1088-99. PubMed ID: 26681731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.